Shield Therapeutics Investor Presentation September 2021

Shield Therapeutics is a London AIM-listed pharmaceutical company focused on developing and commercializing Accrufer®/Feraccru®, a novel oral treatment for iron deficiency in adults approved in the US and EU. The company commenced US commercialization in Q3 2021 and has out-licensed ex-US rights to Norgine, ASK Pharma, and Korea Pharma for key markets including Europe, China, and South Korea.